Immuno-Oncology Associated Myocarditis Patient Data
Description
This dataset contains detailed clinical and laboratory information from patients diagnosed with Immune Checkpoint Inhibitor (ICI)-associated myocarditis. The data was collected retrospectively from August 2018 to August 2024 at the First Affiliated Hospital of the University of Science and Technology of China. It aims to provide insights into the prognostic value of NT-proBNP as a biomarker for adverse outcomes among these patients and to evaluate treatment strategies and patient outcomes.
Files
Steps to reproduce
Data Collection and Research Methods 1. Study Design This study is a single-center retrospective cohort study that analyzed patients diagnosed with Immune Checkpoint Inhibitor (ICI)-associated myocarditis among 7,157 ICI-treated individuals at a tertiary center from August 2018 to August 2024. 2. Data Collection Procedures Source of Data: Electronic medical records (EMR) and laboratory databases. Variables Collected: Patient demographics: age, sex, smoking status. Cancer type and stage. Symptoms of myocarditis. Comorbidities and other concurrent conditions. Line of therapy and specific immunotherapy drugs used. Grade of myocarditis according to ASCO guidelines. Biomarker levels: NT-proBNP, CTnT, CPK, CKMB. Treatment modalities and outcomes 3. Statistical Analysis Software Used: GraphPad Prism 9.0 and R version 4.4.2. Methods: Continuous non-normally distributed variables were reported as median with interquartile range (IQR) and compared using Mann-Whitney U tests in GraphPad Prism. Categorical variables were expressed as absolute frequencies with percentages (%) and analyzed using chi-squared or Fisher's exact tests. Binary logistic regression analyses were conducted in R using the logistf package with Firth's bias-reduced penalized likelihood method